Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MaxCyte, Inc. (MXCT : NSDQ)
 
 • Company Description   
MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.

Number of Employees: 114

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.23 Daily Weekly Monthly
20 Day Moving Average: 734,026 shares
Shares Outstanding: 106.42 (millions)
Market Capitalization: $237.84 (millions)
Beta: 1.23
52 Week High: $5.20
52 Week Low: $2.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.95% -0.67%
12 Week -13.37% -26.01%
Year To Date -46.27% -49.68%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9713 KEY WEST AVENUE SUITE 400
-
ROCKVILLE,MD 20850
USA
ph: 301-944-1700
fax: 301-944-1703
ir@maxcyte.com http://www.maxcyte.com
 
 • General Corporate Information   
Officers
Maher Masoud - President; Chief Executive Officer and Director
Richard Douglas - Chairman
Douglas Swirsky - Chief Financial Officer
Yasir Al-Wakeel - Director
Patrick J. Balthrop - Director

Peer Information
MaxCyte, Inc. (CORR.)
MaxCyte, Inc. (RSPI)
MaxCyte, Inc. (CGXP)
MaxCyte, Inc. (BGEN)
MaxCyte, Inc. (GTBP)
MaxCyte, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 57777K106
SIC: 8731
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 106.42
Most Recent Split Date: (:1)
Beta: 1.23
Market Capitalization: $237.84 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.38 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.19
Price/Cash Flow: -
Price / Sales: 6.31
EPS Growth
vs. Year Ago Period: -11.11%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -8.39%
vs. Previous Quarter: 19.52%
ROE
06/30/25 - -
03/31/25 - -19.90
12/31/24 - -18.94
ROA
06/30/25 - -
03/31/25 - -17.24
12/31/24 - -16.46
Current Ratio
06/30/25 - -
03/31/25 - 12.23
12/31/24 - 10.88
Quick Ratio
06/30/25 - -
03/31/25 - 11.58
12/31/24 - 10.32
Operating Margin
06/30/25 - -
03/31/25 - -110.92
12/31/24 - -106.28
Net Margin
06/30/25 - -
03/31/25 - -110.92
12/31/24 - -106.28
Pre-Tax Margin
06/30/25 - -
03/31/25 - -110.92
12/31/24 - -106.29
Book Value
06/30/25 - -
03/31/25 - 1.88
12/31/24 - 1.95
Inventory Turnover
06/30/25 - -
03/31/25 - 0.74
12/31/24 - 0.67
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©